Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E18.85 EPS (ttm)5.41 Insider Own0.02% Shs Outstand2.82B Perf Week-0.50%
Market Cap287.79B Forward P/E16.09 EPS next Y6.34 Insider Trans1.44% Shs Float2.82B Perf Month-2.89%
Income15.55B PEG2.66 EPS next Q1.43 Inst Own67.40% Short Float0.90% Perf Quarter1.62%
Sales73.54B P/S3.91 EPS this Y24.60% Inst Trans0.00% Short Ratio4.09 Perf Half Y14.77%
Book/sh26.64 P/B3.83 EPS next Y7.10% ROA12.00% Target Price108.25 Perf Year12.56%
Cash/sh10.41 P/C9.79 EPS next 5Y7.10% ROE21.40% 52W Range83.72 - 106.74 Perf YTD12.90%
Dividend2.80 P/FCF- EPS past 5Y1.00% ROI15.00% 52W High-4.48% Beta0.57
Dividend %2.75% Quick Ratio2.10 Sales past 5Y2.30% Gross Margin69.00% 52W Low21.79% ATR1.12
Employees126000 Current Ratio2.40 Sales Q/Q9.10% Oper. Margin28.30% RSI (14)43.08 Volatility0.77% 1.07%
OptionableYes Debt/Eq0.23 EPS Q/Q14.40% Profit Margin21.20% Rel Volume0.97 Prev Close102.11
ShortableYes LT Debt/Eq0.17 EarningsJul 15 BMO Payout48.80% Avg Volume6.20M Price101.96
Recom2.40 SMA20-1.79% SMA50-1.06% SMA2006.73% Volume6,053,900 Change-0.15%
16-Jul-14Reiterated Deutsche Bank Hold $102 → $107
17-Apr-14Reiterated Argus Buy $104 → $116
16-Apr-14Reiterated RBC Capital Mkts Outperform $104 → $106
10-Jan-14Downgrade Barclays Overweight → Equal Weight $99
07-Jan-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
16-Dec-13Reiterated Deutsche Bank Hold $93 → $95
18-Jul-13Reiterated Argus Buy $96 → $104
17-Jul-13Reiterated Barclays Overweight $95 → $99
17-Jul-13Downgrade Deutsche Bank Buy → Hold $92 → $93
18-Apr-13Reiterated Argus Buy $80 → $96
15-Apr-13Reiterated Barclays Overweight $85 → $95
12-Apr-13Reiterated Deutsche Bank Buy $82 → $87
26-Mar-13Reiterated UBS Buy $81 → $87
11-Jan-13Reiterated UBS Buy $76 → $78
04-Jan-13Upgrade Deutsche Bank Hold → Buy $75 → $82
20-Nov-12Initiated Stifel Nicolaus Hold
18-Jul-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
18-Apr-12Reiterated UBS Buy $71 → $70
12-Dec-11Reiterated UBS Buy $72 → $69
17-Oct-11Reiterated UBS Buy $74 → $72
29-Jul-14 04:59PM  IBM Adds Johnson & Johnson CEO, Retired Shell Chief to Board at Bloomberg
04:45PM  U.S. Senate panel to look into price setting for contact lenses Reuters
10:44AM  Top 3 MedTech Stocks, Poised to Gain on Earnings Zacks
06:54AM  [$$] Undervalued Biotech Stocks Beat the Index at Barrons.com
06:32AM  [$$] Beating the Benchmark With Undervalued Biotechs at Barrons.com
28-Jul-14 06:03PM  Omnicom Tops Forecasts Despite Failed Publicis Merger at Investor's Business Daily
05:00PM  Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval Zacks
02:49PM  What Makes Johnson & Johnson a Healthy Dividend Investment at TheStreet
27-Jul-14 09:36PM  Multibillion-Dollar Dispute Over Guidant Seems Headed for Trial at New York Times
09:36PM  Dispute Between Medical Giants Johnson & Johnson and Boston Scientific Moving to Trial at New York Times
25-Jul-14 08:38AM  Zacks Investment Ideas feature highlights: Wal-Mart, Johnson and Johnson and Hewlett-Packard Zacks
07:20AM  Europe backs new leukaemia drugs from J&J and Gilead Reuters
24-Jul-14 04:16PM  YTD Biggest Buyback Companies Trailing S&P In Stock Appreciation Benzinga
02:14PM  Johnson & Johnson partners with Organovo to consider 3D-printing living tissue paidContent.org
01:09PM  Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks Zacks
09:43AM  JNJ: Another Win Added To The Earnings Season at Seeking Alpha
09:23AM  [video] Cramer's Mad Dash: GILD bounces at CNBC
23-Jul-14 06:11PM  Is Gilead About to Crush Pharmacyclics Stock? at Motley Fool
02:18PM  More Questions Raised About Boehringer Ingelheim's Pradaxa at Forbes
07:10AM  Is Alkermes plc Stock Undervalued? at Motley Fool
12:01AM  Who Gets Saved? Hepatitis Cure at $84,000 Makes Doctors Choose Bloomberg
12:01AM  Doctors Dilemma: Who Gets Costly Cure for Deadly Hepatitis C Virus Bloomberg
12:01AM  Doctors Dilemma: Who Gets Costly Cure for Deadly Hepatitis C Virus? Bloomberg
22-Jul-14 02:02PM  3 Quotes From Johnson & Johnson's Conference Call You Need to Read at Motley Fool
01:25PM  Becoming Financially Independent With PepsiCo Dividends at Seeking Alpha
12:42PM  Alexion, 3 Other Top Biotechs Reporting Earnings at Investor's Business Daily
11:38AM  Do This Drug's Sales Make J&J a Hepatitis C Powerhouse? at Motley Fool
10:13AM  Why Johnson & Johnson (JNJ) Stock Is Up Today at TheStreet
21-Jul-14 07:00PM  Drugmakers to share neglected compounds with British academia Reuters
06:17PM  J&J buying back $5 billion worth of its shares AP
06:01PM  [$$] J&J Adds $5 Billion to Stock Buyback Program at The Wall Street Journal
05:20PM  Johnson & Johnson sets $5 billion share buyback at MarketWatch
05:12PM  JOHNSON & JOHNSON Files SEC form 8-K, Other Events EDGAR Online
05:06PM  [video] Johnson & Johnson announces buyback program at CNBC
05:01PM  1 Key Way Obamacare Could Help Johnson & Johnson Stock at Motley Fool
05:00PM  Johnson & Johnson Announces $5 Billion Share Repurchase Program PR Newswire
11:54AM  Johnson & Johnson (JNJ) Declares 70c Quarterly Dividend at TheStreet
11:14AM  Red Flags from Weekly Charts at Forbes
11:10AM  Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2014 PR Newswire
20-Jul-14 10:10AM  Gilead Drug Combination Cures Hepatitis C in HIV Patients Bloomberg
19-Jul-14 11:02AM  Dow Volatility Rises, but Gains for Intel and Microsoft Overpower J&J's Decline at Motley Fool
18-Jul-14 09:06PM  How the Dow's Pharma Stocks Helped Boost Markets Friday at Motley Fool
06:31PM  Its a Good Time to Be a Drugmaker: Why J&J Is Beating Wall Street at Wall St. Cheat Sheet
05:01PM  3 Crucial Questions Johnson & Johnson Needs to Answer at Motley Fool
04:12PM  Why Has Wall Street Punished Johnson & Johnson For Its Earnings Beat? Benzinga
04:01PM  The 4 Stocks That Lifted the Market at 24/7 Wall St.
02:37PM  What You Need to Know About Johnson & Johnson's Best-Selling Drugs at Motley Fool
02:02PM  What Johnson & Johnson Needs to Take the Stock Higher at Motley Fool
02:00PM  Dow Today: Johnson & Johnson (JNJ) Higher at TheStreet
11:40AM  Volvo Ocean Race: A $20 Million Test Of Sailing Endurance at Forbes
17-Jul-14 10:07PM  Even in isolated, pristine Tasmania, pressure to allow GMO farming Reuters
10:04PM  Do Johnson & Johnson's Results Suggest a Pop or Drop for Gilead Sciences? at Motley Fool
02:02PM  Why Johnson & Johnson Keeps Defying Gravity at Motley Fool
11:12AM  Alzheimer's Rates Falling, But Pharma's Search For a Cure Yields No Results Benzinga
10:55AM  No One Ever Got Hurt Owning Johnson and Johnson at Wall St. Cheat Sheet
10:18AM  Sovaldi-$55 billion headache for states at CNBC
08:30AM  Johnson & Johnson Unit Cuts Travel Costs To Hit Financial Goals at The Wall Street Journal
16-Jul-14 03:50PM  [video]Abbott Labs Gets No Respect Despite a Healthy Second Quarter at TheStreet
02:02PM  Keep Calm and Carry On, J&J at Motley Fool
01:29PM  [$$] Johnson & Johnson's Results Boosted by Hepatitis C Drug at The Wall Street Journal
01:00PM  Dow Today: Johnson & Johnson (JNJ) Lower at TheStreet
12:41PM  [$$] Johnson & Johnson's Results Boosted by Hepatitis C Drug at The Wall Street Journal
10:19AM  Todd Harrison: The Curious Timing of Rupert Murdoch at Minyanville
09:10AM  Morgan Stanley Sees Meaningful '15 Headwind For Johnson & Johnson Benzinga
09:01AM  A Surprising Johnson & Johnson Stock Growth Driver, Revealed at Motley Fool
08:09AM  [$$] Johnson & Johnson's Results Boosted by Hepatitis C Drug at The Wall Street Journal
07:52AM  CEO Gorsky Says J&J Getting Products Back on Shelf (Audio) at Bloomberg
06:21AM  Cramer's Lightning Round - General Electric Needs To Bring Good Things To Life (7/15/14) at Seeking Alpha
12:10AM  [$$] Johnson & Johnson's Results Boosted by Hepatitis C Drug at The Wall Street Journal
12:01AM  Petersons Outsider Strategy for J&J Shakes Up Consumer at Bloomberg
15-Jul-14 09:25PM  [$$] Johnson & Johnson's Results Boosted by Hepatitis C Drug at The Wall Street Journal
08:17PM  Sales of New Drugs Increase Johnson & Johnson Profit 13% at New York Times
08:17PM  Sales of New Drugs Increase Johnson & Johnson Profit 13% at New York Times
07:34PM  Why the Market is Wrong about Johnson & Johnson at Motley Fool
07:32PM  [$$] J&J's Results Lifted by Hep C Drug at The Wall Street Journal
06:46PM  [$$] J&J's Results Lifted by Hepatitis C Drug at The Wall Street Journal
06:35PM  Stocks end mixed after Yellen remarks at USA TODAY
05:02PM  If Warren Buffett Ran Health Care at Motley Fool
05:00PM  Video; J&J Earnings Beat Estimates, But Guidance Mixed at Investor's Business Daily
05:00PM  Video: J&J Earnings Beat Estimates, But Guidance Mixed at Investor's Business Daily
04:46PM  Stocks mixed, with Nasdaq hit by valuation worry at CNBC
04:40PM  On The Fly: Closing Wrap at theflyonthewall.com
04:38PM  Stocks end mixed after Yellen remarks at USA TODAY
04:20PM  Stocks End Mostly in Red After Yellen, Earnings, Data Morningstar
04:15PM  Stocks mixed, with Nasdaq hit by valuation worry at CNBC
04:08PM  Stocks end mixed after Yellen remarks at USA TODAY
04:02PM  Johnson & Johnson Ups The Dosage at Motley Fool
04:00PM  Stocks mixed, with Nasdaq hit by valuation worry at CNBC
03:52PM  Does Johnson & Johnson Belong in Your Portfolio? at Wall St. Cheat Sheet
03:34PM  [video] J&J CFO Calls Earnings `Strong,' Guidance `Prudent' at Bloomberg
03:34PM  Johnson & Johnson's (JNJ) CEO Alex Gorsky on Q2 2014 Results - Earnings Call Transcript Seeking Alpha
03:15PM  J&J Earnings Beat Estimates, But Guidance Mixed at Investor's Business Daily
03:09PM  Stocks mixed on Yellen's valuation comments at USA TODAY
03:06PM  Stocks waver amid valuation worry and bank earnings at CNBC
02:43PM  [$$] J&J's Results Lifted by Hepatitis C Drug at The Wall Street Journal
02:39PM  Stocks waver amid valuation worry and bank earnings at CNBC
02:35PM  [video] J&J Would Consider Divesting Businesses, CEO Says at Bloomberg
02:20PM  Stocks drops on Yellen's valuation comments at USA TODAY
02:07PM  [video]Johnson & Johnson Beats on EPS but Sags on a Technical Basis at TheStreet
01:33PM  Tylenol, baby products and Hep C drug boost Johnson & Johnson earnings at CNNMoney.com
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women's health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON'S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COSGROVE STEPHEN JCorporate ControllerMay 05Option Exercise66.1822,0001,455,960112,294May 06 06:10 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Sale100.0522,0002,201,10090,294May 06 06:10 PM
JOHNSON & JOHNSON10% OwnerMay 01Option Exercise5.1672,690375,0801,773,730May 05 02:19 PM
COSGROVE STEPHEN JCorporate ControllerApr 25Option Exercise66.181,51099,93291,293Apr 28 05:03 PM
Fasolo PeterVP, Global Human ResourcesMar 14Sale93.156,824635,64015,647Mar 17 06:10 PM
Fasolo PeterVP, Global Human ResourcesMar 04Option Exercise62.6644,8612,811,19243,571Mar 05 06:18 PM
Ullmann Michael HVP, General CounselJan 10Option Exercise0.009,265065,448Jan 14 06:15 PM
Stoffels PaulusChief Scientific OfficerJan 10Option Exercise0.0018,690035,603Jan 14 06:03 PM
Gorsky AlexChairman, CEOJan 10Option Exercise0.0012,058081,579Jan 14 06:01 PM
Fasolo PeterVP, Worldwide Human ResourcesJan 10Option Exercise0.002,58809,310Jan 14 06:00 PM
COSGROVE STEPHEN JCorporate ControllerJan 10Option Exercise0.002,645090,804Jan 14 05:58 PM
Caruso Dominic JVP, Finance; CFOJan 10Option Exercise0.0012,121065,656Jan 14 05:56 PM
Ullmann Michael HVP, General CounselDec 13Option Exercise53.931,85099,77157,277Dec 16 06:18 PM
Fasolo PeterVP, Worldwide Human ResourcesNov 01Option Exercise0.008,620010,595Nov 05 10:58 AM
MULLIN LEO FDirectorOct 16Option Exercise53.937,600409,86830,752Oct 18 02:30 PM
COSGROVE STEPHEN JCorporate ControllerAug 14Option Exercise53.9325,0001,348,250107,451Aug 16 04:03 PM
COSGROVE STEPHEN JCorporate ControllerAug 14Sale91.3917,2001,571,90890,251Aug 16 04:03 PM
Ullmann Michael HVP, General CounselAug 05Option Exercise0.0020,650071,567Aug 06 05:28 PM
Ullmann Michael HVP, General CounselAug 05Sale93.6816,1401,511,99555,427Aug 06 05:28 PM